Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer

Publication date: September 2017
Source:European Journal of Cancer, Volume 83
Author(s): Geriolda Topi, Roy Ehrnström, Karin Jirström, Ingrid Palmquist, Marie-Louise Lydrup, Anita Sjölander
BackgroundThe oestrogen receptor beta (ERβ) is the predominant oestrogen receptor in the normal colon mucosa and has been reported to exert anti-proliferative and pro-apoptotic effects. However, the role of ERβ in colorectal cancer (CRC) progression remains unclear.AimTo investigate the role of ERβ and its association with hormone status and lifestyle indicators in a female cohort of patients with CRC.MethodsTissue microarrays of primary CRC tumour samples from 320 female patients were conducted with a monoclonal anti-ERβ antibody. The staining intensity was evaluated using immunohistochemistry. The association of ERβ expression with overall survival, disease-free survival, hormone status and lifestyle was evaluated, and effect estimators with 95% confidence intervals (CIs) were reported.ResultsAmong the 314 samples with successfully detected ERβ, 182 (58%) had low expression and 132 (42%) had high expression. The Cox multivariate analysis indicated that patients with high ERβ expression had a decreased risk of overall mortality by 50% (hazard ratio [HR], 0.50; CI, 0.30–0.83) and of cancer recurrence by 76% (HR, 0.24; CI, 0.11–0.52) after adjusting for age, tumour-node-metastasis stage and tumour intravascular invasion. Furthermore, high ERβ expression was significantly correlated with shorter breastfeeding time and longer use of hormone replacement therapy. No association was found between ERβ expression and lifestyle indicators.ConclusionElevated ERβ expression is independently associated with a better prognosis and hormone status but not lifestyle indicators in female CRC patients.



http://ift.tt/2vV5m4C